MacroGenics traded at $3.02 this Wednesday June 29th, increasing $0.01 or 0.33 percent since the previous trading session. Looking back, over the last four weeks, MacroGenics gained 12.97 percent. Over the last 12 months, its price fell by 88.76 percent. Looking ahead, we forecast MacroGenics to be priced at 3.25 by the end of this quarter and at 2.99 in one year, according to Trading Economics global macro models projections and analysts expectations.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Daiichi Sankyo 3,441.00 44.00 1.30% 43.70%
AbbVie 154.14 1.65 1.08% 36.84%
Amgen 245.43 1.92 0.79% 0.69%
AstraZeneca 11,054.00 268.00 2.48% 27.31%
Biogen 205.23 2.72 1.34% -40.73%
Bristol-Myers Squibb 78.28 -0.42 -0.53% 17.15%
Epizyme 1.47 -0.01 -0.68% -82.31%
Genmab 2,259.00 17.00 0.76% -11.96%
Geron 1.52 0.02 1.33% 7.80%
Gilead Sciences 62.48 0.27 0.43% -9.27%
Immunogen 4.36 0.07 1.63% -33.84%
J&J 176.99 0.05 0.03% 7.44%
Karyopharm Therapeutics 4.51 -0.07 -1.53% -56.30%
Eli Lilly 323.00 5.38 1.69% 40.73%
MacroGenics 3.02 0.01 0.33% -88.76%
Merck & Co 92.51 0.62 0.67% 18.95%
Mirati Therapeutics 67.24 -1.26 -1.84% -58.37%
Puma Biotechnology 2.85 0.07 2.52% -68.95%
Pfizer 50.94 0.28 0.55% 30.08%
Regeneron Pharmaceuticals 597.62 3.20 0.54% 4.00%
Roche Holding 319.65 2.10 0.66% -8.29%
Seattle Genetics 179.06 0.59 0.33% 13.42%
Xencor 27.20 0.14 0.52% -21.14%

Indexes Price Day Year
USND 11178 -3.65 -0.03% -22.93%
US2000 1719 -19.47 -1.12% -25.59%

MacroGenics
MacroGenics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies. It has a pipeline of product candidates in human clinical testing, primarily as treatments for different types of cancers, which are created using its technology platforms. Its clinical product candidate, margetuximab, has been enhanced using its Fc Optimization platform. The Company is also developing several product candidates targeting B7-H3, a protein in the B7 family of immune regulator proteins. The Company's product candidates also include enoblituzumab and MGD009, MGC018, MGD006 (flotetuzumab), MGD007, MGD011 (duvortuxizumab), PF-06671008 and MGD010.